Ethics and Drug & Biotechnology Policy
Dr Wendy Lipworth
Forsyth R, Morrell B, Lipworth W, Kerridge I, Jordens C, Chapman, S. Health journalists’ perceptions of their professional roles and responsibilities for ensuring the veracity of reports of health research. Journal of Mass Media Ethics. 2012; 27: 130-41.
Lipworth W, Kerridge I, Little M, Day R. 2012. Evidence and desperation in off-label prescribing: recombinant factor VIIa. British Medical Journal. Published online 16 Jan 2012.
Ghinea N, Lipworth W, Kerridge I, Day R. No evidence or no alternative? Taking responsibility for off-label prescribing. Internal Medicine Journal. 2012; 42(3): 247-51.
Lipworth W, Kerridge I, Day R. Formulating an ethics agenda for drug development, regulation and utilization. Therapeutic Innovation and Regulatory Science. 2012; 47(1): 46-49.
Lipworth W, Kerridge I, Day R. Wrong questions, wrong answers? Are we getting the drugs we need? Clinical Pharmacology & Therapeutics. 2012; 91(3), 367–69.
Lipworth W, Kerridge I, Sweet M, Jordens C, Bonfiglioli C, Forsyth R. Widening the debate about conflict of interest: addressing relationships between journalists and the pharmaceutical industry. Journal of Medical Ethics. 2012; 38(8): 492-95.
Doran E, Robertson J, Salkeld G, Henry D. Pharmaceutical Benefits Scheme Cost Sharing, Patient Cost Consciousness and Prescription Affordability. Australian Health Review. 2011; 35: 37-44.
Lipworth W, Kerridge I, Brett J, Day R. How clinical and research failures lead to suboptimal prescribing: the example of chronic gout. [[i|British Medical Journal]]. Published online 1 Dec 2011.
Lipworth W, Little M, Kerridge I. The perils of proxy outcomes in evidence-based medicine: the case of recombinant factor VIIa. [[i||The International Journal of Person Centered Medicine. 2011; 1(4): 657-59.
Lipworth W, Wodak A, Haber P, Day R. Why is Disulfiram not on the PBS? [[i||Medical Journal of Australia. 2011; 195(7): 371-72 (peer reviewed editorial).
Crowther H, Lipworth W, Kerridge I. EBM and Epistemological Imperialism: Narrowing the divide between evidence and illness. Journal of Evaluation in Clinical Practice. 2011; 17(5): 868-72.
Harvey K, Day R, Campbell W, Lipworth W. Saving money on the PBS: Ranibizumab or Bevacizumab for Neovascular Macular Degeneration? Medical Journal of Australia. 2011; 194 (11): 567-68 (peer reviewed lead editorial).
Inam S, Lipworth W, Kerridge I, Day R. Rethinking the discordance between guidelines and practice in the treatment of rheumatoid arthritis: a failure of practice or failure of evidence? [[i||Medical Journal of Australia. 2011; 195(8): 446-47.
Milder T, Lipworth W, Williams K, Ritchie J, Day R.. "It looks after me”: how older patients make decisions about analgesics for osteoarthritis. Arthritis Care and Research. 2011; 63(9): 1280-86.
Wang N, Lipworth W, Ritchie J, Williams K, Day R.. Eliciting views of Australian Pharmaceutical industry employees on collaboration and the concept of Quality Use of Medicines. Internal Medicine Journal. 2011; 41(4): 314-20.
Milder T, Williams K, Ritchie J, Lipworth W, Day R. Use of NSAIDs for osteoarthritis amongst older-aged primary care patients: Engagement with information and perceptions of risk. Age & Ageing. 2011; 40: 254–59.
Wang N, Lipworth W, Ritchie J, Williams K, Day R. Eliciting views of Australian Pharmaceutical industry employees on collaboration and the concept of Quality Use of Medicines. Internal Medicine Journal. 2011; 41(4): 314-20.
2009 – 2010
Carter SM, Samuel GN, Kerridge I, Day R, Ankeny RA, Jordens CFC, Komesaroff P. Beyond rhetoric in debates about the ethics of marketing prescription medicines to consumers: The importance of vulnerability in people, situations and relationships. American Journal of Bioethics Primary Research. 2010; 1(1): 11-21. From NHMRC 457497.
Chim L, Kelly P, Salkeld G, Stockler M. Are cancer drugs less likely to be recommended for listing by the Pharmaceutical Benefits Advisory Committee in Australia? Pharmacoeconomics. 2010; 28 (6): 463-475.
Samuel G, Jordens CFC, Kerridge I. Direct-to-consumer personal genome testing: Ethical and regulatory issues that arise from wanting to “know” your DNA. Internal Medicine Journal. 2010; 40(3): 220–24.
Doran E and Robertson J Australia’s pharmaceutical cost sharing policy: reducing waste or affordability? Australian Health Review. 2009; 33(2):231-40.
Jordens CFC, Kerridge IH, Samuel G. Direct-to-consumer personal genome testing: The problem is not ignorance; it is market failure. American Journal of Bioethics. 2009; 9(6–7): 13-15.
Doran E and Henry DA. Disease Mongering – exploring the limits of legitimate marketing of medical products. Internal Medicine Journal. 2008; 38: 858–61.
Doran E, Henry DA. Australian Pharmaceutical Policy, Price Control and Drug Innovation in Australia. Journal of Public Health Policy. 2008; 29: 106–20.
Doran E, Henry DA, Faunce TA, Searles A Australian pharmaceutical policy and the idea of innovation. Journal of Australian Political Economy. 2008; 62: 39-61.
Lipworth W, Carter S & Kerridge I. The "EBM movement": where did it come from, where is it going, and why does it matter? Social Epistemology: A Journal of Knowledge, Culture, and Policy. 2008; 22: 425-31.
MacKenzie R, Chapman S, Salkeld G, Holding S. Media influence on Herceptin subsidization in Australia: application of the rule of rescue? J R Soc Med. 2008; 101(6): 305–12.
Mackenzie R, Chapman S, Stiven A, Holding S. The Rule of Rescue and media influence on health policy: Herceptin subsidization in Australia. J Roy Soc Med. 2008; 101:305-12. [Citations:10]
Moynihan R, Doran E, Henry D Disease mongering is now part of the global health debate. PLoS Med. 2008; 5(5): e106. doi:10.1371/journal. pmed.0050106.
Mackenzie FJ, Jordens CFC, Ankeny RA, McPhee J, Kerridge IH. DTCA under the radar: The need for more realistic drugs policy in Australia. Internal Medicine Journal. 2007; 37(4): 224-28.
Doran E, Henry DA. Australian pharmaceutical policy: confused but tough on patients. Internal Medicine Journal. 2006; 36: 211-13.
Doran E, Kerridge I, McNeil P, Henry D. Empirical uncertainty and moral contest: A qualitative analysis of the relationship between medical specialists and the pharmaceutical industry. Social Science and Medicine. 2006; 62: 1510-19.